Corcept Therapeutics vs PACS Group

Corcept Therapeutics (CORT), health care, and PACS Group (PACS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Corcept Therapeutics and PACS Group are valued at about the same: $7.7B and $7.7B. Corcept Therapeutics trades at 52.7 times earnings and PACS Group at 27.6; operating margins in their latest fiscal years were 5.88% and 5.85%. Over the past year Corcept Therapeutics's share price has moved -7.84% and PACS Group's +240%.

Key facts

Corcept Therapeutics market value
$7.7B
PACS Group market value
$7.7B
Corcept Therapeutics P/E
52.7
PACS Group P/E
27.6
Corcept Therapeutics revenue
$761.4MFY to 2025-12-31
PACS Group revenue
$5.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Corcept Therapeutics vs PACS Group: every measure side by side
Measure Corcept Therapeutics PACS Group
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.7Blower$7.7Bhigher
Revenue$761.4Mlower$5.3Bhigher
Earnings$99.7Mlower$191.5Mhigher
Employees730lower47,455higher
Total assets$836.7Mlower$5.6Bhigher
Valuation
P/E52.7higher27.6lower
P/S10.1higher1.5lower
P/B9.2higher6.3lower
Dividend yield0.00%0.00%
Profitability
Operating margin5.88%higher5.85%lower
Balance sheet
Net assets$647.8Mlower$946.8Mhigher
Total liabilities$188.8Mlower$4.6Bhigher
Total debt—$353.2M
Cash on hand$120.5Mlower$197Mhigher
Price change
Today+1.23%higher-0.92%lower
1 year-7.84%lower+240%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Corcept Therapeutics only (1)

PACS Group only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns CORT · Who owns PACS

Further comparisons

Learn

Questions and answers

Which is bigger, Corcept Therapeutics or PACS Group?

By market value, PACS Group is the larger: $7.7B against $7.7B for Corcept Therapeutics. By revenue in its latest fiscal year, PACS Group is the larger: $5.3B against $761.4M for Corcept Therapeutics.

Which has the higher P/E ratio?

Corcept Therapeutics: 52.7, against 27.6 for PACS Group. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Corcept Therapeutics: 5.88%, against 5.85% for PACS Group. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Corcept Therapeutics and PACS Group?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Corcept Therapeutics and 1 holds PACS Group.

Cite this page

Funkfolio, “Corcept Therapeutics vs PACS Group”, data as of 18 November 2026. https://funkfolio.com/compare/cort-vs-pacs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.